Sanofi has announced that it entered into an agreement to acquire Origimm Biotechnology, an Austrian privately owned biotechnology company specialising in the discovery of virulent skin microbiome components and antigens from bacteria causing skin disease, such as acne.
The transaction adds to Sanofi pipeline a potential first-in-class vaccine candidate in acne vulgaris, a condition affecting millions of people worldwide. The acquisition is expected to close early December 2021.
